Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Latest News

Venetoclax showed “remarkable efficacy” in older patients, with an response rate of 91% in the octogenarian group—similar to what has been reported in younger cohorts. | Image credit: sovova - stock.adobe.com
Venetoclax Effective in Older Patients With CLL

June 20th 2025

Venetoclax demonstrated impressive efficacy in octogenarians with CLL, although treatment management posed some challenges.

Cytogenetic risk factors do not appear to affect survival outcomes following first-line ibrutinib for CLL/SLL, real-world survival data suggest. | Image credit: Saiful52 - stock.adobe.com
First-Line Ibrutinib Effective in CLL/SLL With or Without Risk Factors

June 13th 2025

The tablet formulation of zanubrutinib (Brukinsa; BeOne) is now approved for all 5 indications across several hematological cancers. | Image credit: wladimir1804 - AdobeStock_408414612
FDA Approves Tablet Formulation of Zanubrutinib for All Indications

June 11th 2025

While improvements were seen in non-relapse mortality in CLL throughout the decade, the researchers observed no differences in overall survival or progression-free survival. | Image credit: LASZLO - stock.adobe.com
New Era of CLL Treatments Brings Changes to Use of HSCT

June 9th 2025

The overall response rate with first-line zanubrutinib for CLL reached 97.3%, with 18.2% of patients experiencing complete response or complete response with incomplete hematologic recovery. | Image Credit: jarun011 - stock.adobe.com
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial

June 6th 2025

More News

CLL cells magnified/stained | image credit: jarun011 - stock.adobe.com
December 10th 2024

6-Year Data Support Fixed-Duration Ven-Obi for Untreated CLL

Jared Kaltwasser
Long-term data support the safety and efficacy of venetoclax (Venclexta) and obinutuzumab (Gazyva) in chronic lymphocytic leukemia (CLL), though questions remain about which patients would benefit most from the regimen.
Guidelines folder-tashatuvango-stock.adobe.com.jpeg
December 2nd 2024

New Guidelines Clarify EORTC Quality of Life Scores for Chronic Lymphocytic Leukemia

Karen Jacobson-Sive
Meaningful change thresholds for the EORTC Quality of Life Questionnaire in chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) are: −11/+11 for symptom burden, −16/+16 for physical condition/fatigue, and −16/+13 for worries/fears.
New evidence suggest a slight connection between receiving a tattoo and elevated cancer risks | image credit: xartproduction - stock.adobe.com
November 29th 2024

Tattoos May Be Associated With Increased Risk of Rare NHLs

AJMC Contributor
Despite found associations, due to small sample sizes the researchers suggest readers interpret their findings with caution.
Big Data | Image Credit: © Friends Stock-stock.adobe.com
November 26th 2024

Real-World Data Confirm Ibrutinib's Role in Relapsed CLL

Gayle Turim Dickstein
This multiyear follow-up of more than 3300 patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) who received ibrutinib—the longest study of its kind—confirms the agent’s efficacy as a salvage treatment but reveals new information about its impact in different subpopulations with varying clinical characteristics.
Older woman taking out dose of pills from glass bottle | Image Credit: © fizkes - stock.adobe.com
November 23rd 2024

Novel Relapsed/Refractory CLL Therapies Have Similar Safety Profiles

Jared Kaltwasser
The new report is an attempt to provide comprehensive safety data on the rapidly changing treatment landscape for relapsed or refractory chronic lymphocytic leukemia (CLL).
CLL over the image of a stethoscope and red blood cells | Image credit: Saiful52 - stock.adobe.com
November 21st 2024

Treating Double-Exposed Patients With CLL: A Continued Unmet Need

Gayle Turim Dickstein
For patients with chronic lymphocytic leukemia (CLL) treated previously with venetoclax and Bruton’s tyrosine kinase inhibitors, many more trials are needed to pinpoint the best next steps
Health care costs and fees | Image Credit: © everythingpossible - stock.adobe.com
November 9th 2024

Fixed-Duration 1L CLL Treatment Reduces Long-Term Costs in the Real World

AJMC Contributor
The venetoclax-based regimen was associated with an approximate $8000 decrease in costs compared with the continuous Bruton tyrosine kinase inhibitor treatment 6 months after the fixed-duration period.
NK Cell test | Image Credit: © jarun011-stock.adobe.com
November 6th 2024

KIR2DS2+ NK Cells Show Potential in HCC and Leukemia Treatment

AJMC Contributor
These findings suggest that KIR2DS2-positive (KIR2DS2+) natural killer (NK) cells could be an attractive therapeutic target for in vivo strategies, although enhanced effector function is lost during ex vivo expansion needed for NK cell–based therapies, such as chimeric antigen receptor–NK cell treatment.
Respiratory tract infections may occur in patients with CLL taking BTK inhibitors | image credit: Worldillustrator - stock.adobe.com
November 2nd 2024

Review Emphasizes Potential Infection Risks With BTK Inhibitors

Gayle Turim Dickstein
Although Bruton tyrosine kinase (BTK) inhibitor monotherapy in chronic lymphocytic leukemia (CLL) has been a game-changer, patients have significantly increased risks of infection, especially in the upper respiratory tract.
Stethoscope chart graph data | Image Credit: © amazing studio - stock.adobe.com
October 30th 2024

Zanubrutinib More Effective Than Ibrutinib in Treating Patients With Relapsed/Refractory CLL, SLL

Karen Jacobson-Sive
The long-term response rate for zanubrutinib was better than ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Ibrutinib molecule | image credit: molekuul.be - stock.adobe.com
October 23rd 2024

Understanding Ibrutinib Relapse in CLL: Immune Profiles of Responders vs Relapsing Patients

Kimberly Rath, PharmD
A new study identifies potential immune profile differences in patients with chronic lymphocytic leukemia (CLL) that may lead to resistance after ibrutinib therapy.
money and stethoscope | Image Credit: © pla2na - stock.adobe.com
October 17th 2024

Zanubrutinib Not Cost-Effective in China Against Fixed-Duration R-Bendamustine in 1L CLL

AJMC Contributor
The study found that the price tag for the second-generation Bruton tyrosine kinase inhibitor would need to be reduced by 30% in order to be cost-effective compared with bendamustine-rituximab (R-bendamustine) for these patients.
Skin Cancer Potential | Image Credit: © Monstar Studio-stock.adobe.com
October 16th 2024

Melanoma Risk Doubled for Monoclonal B-Cell Lymphocytosis

Karen Jacobson-Sive
Patients with low-count chronic lymphocytic leukemia phenotype monoclonal B-cell lymphocytosis had a 1.86-fold greater risk of melanoma.
Acalabrutinib demonstrates superior safety over ibrutinib in the treatment of CLL/SLL | image credit: sovova - stock.adobe.com
October 9th 2024

Real-World Data: Acalabrutinib Safety Profile Superior in CLL/SLL

Jared Kaltwasser
A comparison of the second-generation Bruton tyrosine kinase (BTK) inhibitor acalabrutinib to the first-generation ibrutinib shows the former had lower rates of adverse events in a real-world setting.
diagnosis leukemia | Image Credit: © Vitalii Vodolazskyi - stock.adobe.com
October 4th 2024

Real-World Data Support TKI Discontinuation After CP-CML Remission

Jared Kaltwasser
Most patients diagnosed with chronic-phase chronic myeloid leukemia (CP-CML) who achieved a deep molecular response on tyrosine kinase inhibitor (TKI) therapy were able to avoid relapse despite discontinuing therapy.
CAR T cell | Image Credit: © Christoph Burgstedt - stock.adobe.com
October 3rd 2024

B-Cell Activating Factor Receptor CAR T Therapy Holds Promise for CLL

Karen Jacobson-Sive
B-cell activating factor receptor chimeric antigen receptor (CAR) T-cell therapy caused cytotoxic effects on all chronic lymphocytic leukemia (CLL) cell lines.
Clinical research | Image Credit: © peshkova-stock.adobe.com
September 27th 2024

Venetoclax Plus Rituximab Supports Immune Recovery in CLL

Kimberly Rath, PharmD
Researchers report on the long-term immune changes in patients with refractory or relapsed chronic lymphocytic leukemia (CLL) treated with venetoclax and rituximab plus bendamustine and rituximab.
Understanding genetic alterations in CLL could improve personalized medicine strategies | image credit: Shuo - stock.adobe.com
September 24th 2024

Exploring the Impact of TP53 Alterations on miR-34a and NOTCH1 in CLL

Kimberly Rath, PharmD
New study provides insights into the relationship between TP53, miR-34a, and NOTCH1 in CLL cells.
Doctor consulting with a patient | Image Credit: © bnenin - stock.adobe.com
September 19th 2024

Gaps Apparent in Physicians’ Knowledge of CLL, MCL

Nameera Temkar, MD
Physicians in the US, Germany, and France show gaps in their knowledge of the treatment of of refractory/relapsed chronic lymphocytic leukemia (CLL) and mantle Cell lymphoma (MCL).
Image credit: Laszlo-stock.adobe.com
September 13th 2024

Predicting Survival in CLL: The Power of Measurable Residual Disease

Kimberly Rath, PharmD
Undetectable measurable residual disease rates can help predict progression-free survival in patients with chronic lymphocytic leukemia, according to an analysis.
Doctor holding heart | Image Credit: © Pana Studio - stock.adobe.com
September 12th 2024

Acalabrutinib vs Ibrutinib: Real-World Insights Into Safety Differences for Patients With CLL

Kimberly Rath, PharmD
The latest study findings suggest that acalabrutinib may be a safer option than ibrutinib for patients with chronic lymphocytic leukemia, offering a lower risk of serious cardiovascular and infection-related adverse events.
red blood cells model CLL | image credit: digitalpochi - stock.adobe.com
September 4th 2024

B-Cell Activating Factor Levels May Predict Reduced Risk of CLL, Study Finds

Kimberly Rath, PharmD
A recent study has found that higher serum levels of B-cell activating factor and anti-CCP3 are associated with a reduced risk of developing chronic lymphocytic leukemia (CLL), suggesting potential biomarkers for assessing CLL risk.
Skin cancer is a dangerous morbidity risk in patients with CLL | image credit: Ocskay Mark - stock.adobe.com
August 26th 2024

Study Implicates AXL in Skin Cancer Development in CLL

Jared Kaltwasser
The authors said their findings also suggest AXL inhibition might be an important therapeutic strategy.
CLL cells | image credit: Arif Biswas - stock.adobe.com
August 19th 2024

Novel Targeted Therapies Show Superiority in Relapsed/Refractory CLL

Nameera Temkar, MD
A meta-analysis demonstrated the superiority of Bruton tyrosine kinase inhibitors (BKTi) in the overall survival of patients with chronic lymphocytic leukemia compared with other therapies.
CLL | Image Credit: Saiful52-stock.adobe.com
August 16th 2024

New Model Offers Indicators of Ibrutinib Response in CLL

Jared Kaltwasser
A mathematical model using pharmacodynamic parameters, including duration of hyperlymphocytosis, may help clinicians better predict patient responses to ibrutinib administered for chronic lymphocytic leukemia (CLL).
DNA helix inside blood drop | Image credit: Елена Бутусова - stock.adobe.com
August 12th 2024

NGS-Based Risk Stratification, Treatment Shows Cost-Effectiveness in CLL

AJMC Contributor
A Canadian study showed a high probability that using next-generation sequencing (NGS) for treatment sequencing based on risk stratification is cost-effective.
Precision medicine | Image Credit: leowolfert-stock.adobe.com
August 8th 2024

Opportunities Remain for Expanding Precision Medicine in CLL

AJMC Contributor
As the treatment landscape for chronic lymphocytic leukemia (CLL) has moved into an era where targeted treatments are a mainstay of treatment, new opportunities to tailor therapy have emerged.
biomarker word cloud | Image Credit: laufer-stock.adobe.com
August 4th 2024

Biomarker Incorporated Into Novel CLL Outcome Prediction Model

Gayle Turim Dickstein
Researchers believe that in their revised 4-factor model to predict patient outcomes in chronic lymphocytic leukemia (CLL), CD49d tops lactate dehydrogenase.
concept of a genetic mutation | Image Credit: © lucadp - stock.adobe.com
August 1st 2024

Co-Occurrence of del(6q), RPS15 May Drive Poor Prognosis in CLL

AJMC Contributor
The findings support previous research suggesting that worse prognosis in patients with del(6q) is not solely a result of genomic instability or presence of multiple genetic alterations.
Clinical link research | Image Credit: sdecoret - stock.adobe.com
July 27th 2024

MRD, Clinical Outcomes Linked in Chronic Leukemia

Gayle Turim Dickstein
This systematic review focusing on the targeted therapy era found solid associations between measurable residual disease (MRD) and clinical outcomes in patients with chronic lymphocytic leukemia.
<123456>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo